György M. Keserű H2020 FRAGNET Network Hungarian Academy of Sciences
|
|
- Amberlynn Sharp
- 5 years ago
- Views:
Transcription
1 Fragment based lead discovery - introduction György M. Keserű H2020 FRAGET etwork Hungarian Academy of Sciences
2 Hit discovery from screening Druglike library Fragment library Large molecules (MW>300) Small molecules (MW<300) Large library (10 6 compound) Small library (10 3 fragment) Biochemical testing Biophysical testing Less diverse hits Diverse hits High affinity (1-10 mm) Low affinity (<100 mm)
3 What do we call fragments? Simple, small, polar molecules Rule of 3: MW < 300 ( heavy < 22) Log P < 3 umber of H-donors < 3 umber of H-acceptors < 3 Further properties: umber of rot. bonds < 4 Polar surface < 60 Å 2 Good solubility
4 Why fragments are beneficial? They have good physchem profile A smaller library contains more chemical information Their chemical space is smaller: better sampling They bind to protein hot spots They provide rational optimization towards drugs
5 Fragment space is smaller Druglike compounds Estimated number: Compounds in Chemical Abstract Registry: 113x10 6 Compounds commercially available: 10 6 umber of compounds screened: 10 5 Fragments Estimated number: (max 17 C,,, H, S, Cl atom):10 11 Fragments commercially available: 10 5 umber of compounds screened:
6 Sampling is more efficient HSP90 Clinical Candidates Fragment hits from a screen of 719 fragments H H H 2 H Cl H Me Me Me Me H 2 H H H H 2 H 2 H H S CF 3 H 2 H H 2 H H 2 H S H 2 J. Med. Chem. 2011, 54, Key features of all known clinical candidates are represented in hits from a small fragment library
7 Fragments bind to hot spots FRAGMETS FRAGMETS Fragments form limited number of polar interactions within a small region of protein binding sites Keserű JCIM 2012, Vajda PAS 2015, Keserű DDT 2017
8 Rational optimation strategies Linking Growing
9 What do we need for an FBDD program? Fragment library Screening technology Structural information (preferred) ptimization strategy
10 What are the general features of a good fragment? Interactions Diverse polar groups Pharmacophore variety Scaffold variety Physicochemical properties Size, complexity Shape Lipophilicity Solubility Synthetic vectors for growing Reactivity, stability, aggregation Synthetic tractability, cost MW = 278 clogp=1.84 Murray, Rees Angew. Chem. Int. Ed. 2015, 54, 2 7
11 Fragment sources Boyd, Kloe DDT Technologies 2010, 7, e173
12 How to design a library? Level 1 Compound properties Level 2 Sampling Level 3 MedChem Level 4 Experimental Physicochemical Reactivity Aggregator, assay interference Availability Priviledged structure Pharmacophore diversity Scaffold diversity Analogue accessibility Synthetic tractability Stability Purity Solubility Stability Cost Shape diversity Chris Swain (CMC): 1216 fragment hits, 240 publications, 174 molecular targets, 26 detection technologies
13 Physicochemical Fragment size and lipophilicity Libs Hits Libs Hits Chris Swain, CMC
14 Sampling of the fragment space Scaffold diversity Diversity Pharmacophore diversity 2 common bits, 3 bits in both reference and database mols, Tanimoto coeff. = 0.5 Hubbard et al. J Comput Aided Mol Des (2009) 23: common, 2 A-specific, 7 B-specific triangles Tanimoto coeff. = 0.29
15 MedChem and experimental MedChem considerations Multiple synthetically accessible vectors Should be synthesizable in <4 steps Analogues should be available Use racemates Experimental evaluation Purity should be 95% or higher Aqueous solubility (preferably 5 mm in 5% DMS, or other screening co-solvents) Stability (>24 h in solution) MedChem Experimental
16 Screening and structural information Keserű et al. J. Med. Chem. 2016
17 Fragment screening strategy Primary Screening Thermal Shift / SPR / MR Thermal Shift MR Secondary Screening MR Spectroscopy X-Ray ITC Binding Affinity ITC / SPR/ Biochem Biochem SPR Christina Spry
18 ptimization metrics Ligand efficiency indices connect the complexity model to ligandprotein interactions Ligand efficiency concept LE = DG/ hev preferentially >0.3 SILE= DG/( hev ) 0.3 preferentially >0.3 Lipophilic efficiency metrics LLE = ppot logp preferentially >4 LELP = logp / LE preferentially <10 LLE AT (= (LLE/ hev )) preferentially >0.3 LE LLE AT
19 Plexxicon B-Raf inhibitor B-Raf V600E is the most frequently observed oncogenic mutation Screen of 20,000 compounds ( Da) at 200uM against Pim-1, p38, and CSK 238 compounds with 200uM subjected to crystallography: >100 structures solved 7-Azaindole included among hits (IC50 > 200uM) but had different binding modes in the ATP site of the 4 asymetric units of Pim-1 But its derivatives showed conserved binding mode across 3 different kinases! 3-aminophenyl a general motif based on Pim-1 structure 3-benzyl binds similarly to FGFR1 PLX4720 bound to B-Raf 19 PAS, 2008, 105, 3041.
20 B-Raf Hit Progression Based on structures against 17 kinases the azaindole 3,4 and 5 positions were targeted for chemical derivatizations Series & selectivity progression: Binding into a Raf selective pocket Selectivity of the initial fragment hits is not important! 20 PAS, 2008, 105, 3041.
21 Astex HSP90 inhibitor 1,600 fragments were screened with a hit contained motifs similar to those of Radicicol (a natural product) Design for interaction with Lys58 or displacement of Lys58 Compound 3 ew pocket formed with Lys58 moving Compound 4 J. Med. Chem. 2010, 53, 5942 J. Med. Chem. 2010, 53, 5956.
22 Astex HSP90 inhibitor Radicicol like scaffold
23 Abbvie Bcl2 inhibitor 2 nd site 1 st site J. Med. Chem. 2006, 49, J. Med. Chem. 2008, 51, at. Med ,
24 Abbvie Bcl2 inhibitor K i < 0.5 nm MW 973
25 Acknowledgement Dan Erlanson György Ferenczy Mike Hann Chris Murray Stephen Pickett Chris Swain
Enamine Golden Fragment Library
Enamine Golden Fragment Library 14 March 216 1794 compounds deliverable as entire set or as selected items. Fragment Based Drug Discovery (FBDD) [1,2] demonstrates remarkable results: more than 3 compounds
More informationBuilding innovative drug discovery alliances
Building innovative drug discovery alliances Hit optimisation o using fragments Mark kwhittaker Evotec AG, Fragments 2015, March 2015 Agenda Fragment optimisation in an ideal world Fragment optimisation
More informationIntroduction to FBDD Fragment screening methods and library design
Introduction to FBDD Fragment screening methods and library design Samantha Hughes, PhD Fragments 2013 RSC BMCS Workshop 3 rd March 2013 Copyright 2013 Galapagos NV Why fragment screening methods? Guess
More informationChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD)
ChemDiv Beyond the Flatland 3D-Fragment Library for Fragment-Based Drug Discovery (FBDD) CEMDIV BEYD TE FLATLAD 3D-FRAGMET LIBRARY BACKGRUD Fragment-based drug discovery (FBDD) has become an efficient
More informationDr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre
Dr. Sander B. Nabuurs Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre The road to new drugs. How to find new hits? High Throughput
More informationReceptor Based Drug Design (1)
Induced Fit Model For more than 100 years, the behaviour of enzymes had been explained by the "lock-and-key" mechanism developed by pioneering German chemist Emil Fischer. Fischer thought that the chemicals
More informationAdvanced Medicinal Chemistry SLIDES B
Advanced Medicinal Chemistry Filippo Minutolo CFU 3 (21 hours) SLIDES B Drug likeness - ADME two contradictory physico-chemical parameters to balance: 1) aqueous solubility 2) lipid membrane permeability
More informationIntroduction. OntoChem
Introduction ntochem Providing drug discovery knowledge & small molecules... Supporting the task of medicinal chemistry Allows selecting best possible small molecule starting point From target to leads
More informationImportant Aspects of Fragment Screening Collection Design
Important Aspects of Fragment Screening Collection Design Phil Cox, Ph. D., Discovery Chemistry and Technology, AbbVie, USA Cresset User Group Meeting, Cambridge UK. Thursday, June 29 th 2017 Disclosure-
More informationFRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC )
FRAGMENT SCREENING IN LEAD DISCOVERY BY WEAK AFFINITY CHROMATOGRAPHY (WAC ) SARomics Biostructures AB & Red Glead Discovery AB Medicon Village, Lund, Sweden Fragment-based lead discovery The basic idea:
More informationDesign and Synthesis of 3-Dimensional Fragments to Explore Pharmaceutical Space
Design and Synthesis of 3-Dimensional Fragments to Explore Pharmaceutical Space Mary Christine Wheldon Doctor of Philosophy University of York Chemistry September 2016 Abstract This thesis describes an
More informationComputational chemical biology to address non-traditional drug targets. John Karanicolas
Computational chemical biology to address non-traditional drug targets John Karanicolas Our computational toolbox Structure-based approaches Ligand-based approaches Detailed MD simulations 2D fingerprints
More informationUsing AutoDock for Virtual Screening
Using AutoDock for Virtual Screening CUHK Croucher ASI Workshop 2011 Stefano Forli, PhD Prof. Arthur J. Olson, Ph.D Molecular Graphics Lab Screening and Virtual Screening The ultimate tool for identifying
More informationImplementation of novel tools to facilitate fragment-based drug discovery by NMR:
Implementation of novel tools to facilitate fragment-based drug discovery by NMR: Automated analysis of large sets of ligand-observed NMR binding data and 19 F methods Andreas Lingel Global Discovery Chemistry
More informationFragment Based Drug Design: From Experimental to Computational Approaches
Current Medicinal Chemistry, 2012, 19,????-???? 1 Fragment Based Drug Design: From Experimental to Computational Approaches A. Kumar, A. Voet and K.Y.J. Zhang* Zhang Initiative Research Unit, Advanced
More informationComputational Methods and Drug-Likeness. Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004
Computational Methods and Drug-Likeness Benjamin Georgi und Philip Groth Pharmakokinetik WS 2003/2004 The Problem Drug development in pharmaceutical industry: >8-12 years time ~$800m costs >90% failure
More informationApplications of Fragment Based Approaches
Applications of Fragment Based Approaches Ben Davis Vernalis R&D, Cambridge UK b.davis@vernalis.com 1 Applications of Fragment Based Approaches creening fragment libraries Techniques Vernalis eeds approach
More informationChemical library design
Chemical library design Pavel Polishchuk Institute of Molecular and Translational Medicine Palacky University pavlo.polishchuk@upol.cz Drug development workflow Vistoli G., et al., Drug Discovery Today,
More informationFragment based drug discovery in teams of medicinal and computational chemists. Carsten Detering
Fragment based drug discovery in teams of medicinal and computational chemists Carsten Detering BioSolveIT Quick Facts Founded in 2001 by the developers of FlexX ~20 people Core expertise: docking, screening,
More informationFragment Screening in Drug Discovery
Fragment Screening in Drug Discovery Marc Martinell SEQT, Sitges, 19th-20th October 2006 Crystax Pharmaceuticals SL Barcelona Science Park Josep Samitier 1-5, E-08028 Barcelona Tel: +34 93 403 4703 Fax
More informationPerspectiVe. Recent Developments in Fragment-Based Drug Discovery. 1. Introduction. 2. Trends and Developments
J. Med. Chem. XXXX, xxx, 000 A PerspectiVe Recent Developments in Fragment-Based Drug Discovery Miles Congreve,* Gianni Chessari, Dominic Tisi, and Andrew J. Woodhead Astex Therapeutics Ltd., 436 Cambridge
More informationIntroduction to Chemoinformatics and Drug Discovery
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013 The Chemical Space There are atoms and space. Everything else is opinion. Democritus (ca.
More informationHit to Lead Michael Rafferty
it to Lead 1 Ph.D. Department of Medicinal Chemistry University of Kansas raffe01@ku.edu Background Ph.D. Medicinal Chemistry, University of Kansas Postdoctoral Fellowship, I 25+ years experience in drug
More informationUnlocking the potential of your drug discovery programme
Unlocking the potential of your drug discovery programme Innovative screening The leading fragment screening platform with MicroScale Thermophoresis at its core Domainex expertise High quality results
More informationComputational Chemistry in Drug Design. Xavier Fradera Barcelona, 17/4/2007
Computational Chemistry in Drug Design Xavier Fradera Barcelona, 17/4/2007 verview Introduction and background Drug Design Cycle Computational methods Chemoinformatics Ligand Based Methods Structure Based
More informationStructure-Based Drug Discovery An Overview
Structure-Based Drug Discovery An Overview Edited by Roderick E. Hubbard University of York, Heslington, York, UK and Vernalis (R&D) Ltd, Abington, Cambridge, UK RSC Publishing Contents Chapter 1 3D Structure
More informationVirtual Screening: How Are We Doing?
Virtual Screening: How Are We Doing? Mark E. Snow, James Dunbar, Lakshmi Narasimhan, Jack A. Bikker, Dan Ortwine, Christopher Whitehead, Yiannis Kaznessis, Dave Moreland, Christine Humblet Pfizer Global
More informationHydrogen Bonding & Molecular Design Peter
Hydrogen Bonding & Molecular Design Peter Kenny(pwk.pub.2008@gmail.com) Hydrogen Bonding in Drug Discovery & Development Interactions between drug and water molecules (Solubility, distribution, permeability,
More informationDesign and Synthesis of the Comprehensive Fragment Library
YOUR INNOVATIVE CHEMISTRY PARTNER IN DRUG DISCOVERY Design and Synthesis of the Comprehensive Fragment Library A 3D Enabled Library for Medicinal Chemistry Discovery Warren S Wade 1, Kuei-Lin Chang 1,
More informationChemogenomic: Approaches to Rational Drug Design. Jonas Skjødt Møller
Chemogenomic: Approaches to Rational Drug Design Jonas Skjødt Møller Chemogenomic Chemistry Biology Chemical biology Medical chemistry Chemical genetics Chemoinformatics Bioinformatics Chemoproteomics
More informationAMRI COMPOUND LIBRARY CONSORTIUM: A NOVEL WAY TO FILL YOUR DRUG PIPELINE
AMRI COMPOUD LIBRARY COSORTIUM: A OVEL WAY TO FILL YOUR DRUG PIPELIE Muralikrishna Valluri, PhD & Douglas B. Kitchen, PhD Summary The creation of high-quality, innovative small molecule leads is a continual
More informationVirtual screening for drug discovery. Markus Lill Purdue University
Virtual screening for drug discovery Markus Lill Purdue University mlill@purdue.edu Lecture material http://people.pharmacy.purdue.edu/~mlill/teaching/eidelberg/ I.1 Drug discovery Cl N Disease I.1 Drug
More informationStructural biology and drug design: An overview
Structural biology and drug design: An overview livier Taboureau Assitant professor Chemoinformatics group-cbs-dtu otab@cbs.dtu.dk Drug discovery Drug and drug design A drug is a key molecule involved
More informationRetrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a
Retrieving hits through in silico screening and expert assessment M.. Drwal a,b and R. Griffith a a: School of Medical Sciences/Pharmacology, USW, Sydney, Australia b: Charité Berlin, Germany Abstract:
More informationMedicinal Chemist s Relationship with Additivity: Are we Taking the Fundamentals for Granted?
Medicinal Chemist s Relationship with Additivity: Are we Taking the Fundamentals for Granted? J. Guy Breitenbucher Streamlining Drug Discovery Conference San Francisco, CA ct. 25, 2018 Additivity as the
More informationFragment Hotspot Maps: A CSD-derived Method for Hotspot identification
Fragment Hotspot Maps: A CSD-derived Method for Hotspot identification Chris Radoux www.ccdc.cam.ac.uk radoux@ccdc.cam.ac.uk 1 Introduction Hotspots Strongly attractive to organic molecules Organic molecules
More informationEasier and Better Exploitation of PhysChem Properties in Medicinal Chemistry
www.acdlabs.com Easier and Better Exploitation of PhysChem Properties in Medicinal Chemistry Dr. Sanjivanjit K. Bhal Advanced Chemistry Development, Inc. (ACD/Labs) Evolution of MedChem
More informationStructure based drug design and LIE models for GPCRs
Structure based drug design and LIE models for GPCRs Peter Kolb kolb@docking.org Shoichet Lab ACS 237 th National Meeting, March 24, 2009 p.1/26 [Acknowledgements] Brian Shoichet John Irwin Mike Keiser
More informationDevelopment of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining
Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining Samer Haidar 1, Zouhair Bouaziz 2, Christelle Marminon 2, Tiomo Laitinen 3, Anti Poso
More informationThesis. Budapest University of Technology and Economics Inorganic and Analytical Chemistry Department. PhD student Márton Vass Gedeon Richter Plc.
Budapest University of Technology and Economics Inorganic and Analytical Chemistry Department Thesis PhD student Márton Vass Gedeon Richter Plc. Supervisor Dr. György Miklós Keserű Research Centre for
More informationVirtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME
Virtual Libraries and Virtual Screening in Drug Discovery Processes using KNIME Iván Solt Solutions for Cheminformatics Drug Discovery Strategies for known targets High-Throughput Screening (HTS) Cells
More informationTargeting protein-protein interactions: A hot topic in drug discovery
Michal Kamenicky; Maria Bräuer; Katrin Volk; Kamil Ödner; Christian Klein; Norbert Müller Targeting protein-protein interactions: A hot topic in drug discovery 104 Biomedizin Innovativ patientinnenfokussierte,
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract research
More informationMedicinal Chemistry and Chemical Biology
Medicinal Chemistry and Chemical Biology Activities Drug Discovery Imaging Chemical Biology Computational Chemistry Natural Product Synthesis Current Staff Mike Waring Professor of Medicinal Chemistry
More informationBuilding innovative drug discovery alliances. Just in KNIME: Successful Process Driven Drug Discovery
Building innovative drug discovery alliances Just in KIME: Successful Process Driven Drug Discovery Berlin KIME Spring Summit, Feb 2016 Research Informatics @ Evotec Evotec s worldwide operations 2 Pharmaceuticals
More informationAlkane/water partition coefficients and hydrogen bonding. Peter Kenny
Alkane/water partition coefficients and hydrogen bonding Peter Kenny (pwk.pub.2008@gmail.com) Neglect of hydrogen bond strength: A recurring theme in medicinal chemistry Rule of 5 Rule of 3 Scoring functions
More informationDispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses
Dispensing Processes Profoundly Impact Biological, Computational and Statistical Analyses Sean Ekins 1, Joe Olechno 2 Antony J. Williams 3 1 Collaborations in Chemistry, Fuquay Varina, NC. 2 Labcyte Inc,
More informationAutomated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity. Darren Green GSK
Automated Compound Collection Enhancement: how Pipeline Pilot preserved our sanity Darren Green GSK The Compound Collection Enhancement Challenge A diversity of ideas Which are novel Which have the desired
More informationIntroduction to Fragment-based Drug Discovery
1 Introduction to Fragment-based Drug Discovery 1.1 Introduction Mike Cherry and Tim Mitchell Fragment screening is the process of identifying relatively simple, often weakly potent, bioactive molecules.
More informationSynthetic organic compounds
Synthetic organic compounds for research and drug discovery chemicals Compounds for TS Fragment libraries Target-focused libraries Chemical building blocks Custom synthesis Drug discovery services Contract
More informationSimilarity Search. Uwe Koch
Similarity Search Uwe Koch Similarity Search The similar property principle: strurally similar molecules tend to have similar properties. However, structure property discontinuities occur frequently. Relevance
More informationIsothermal Titration Calorimetry in Drug Discovery. Geoff Holdgate Structure & Biophysics, Discovery Sciences, AstraZeneca October 2017
Isothermal Titration Calorimetry in Drug Discovery Geoff Holdgate Structure & Biophysics, Discovery Sciences, AstraZeneca October 217 Introduction Introduction to ITC Strengths / weaknesses & what is required
More informationPrinciples of Drug Design
Advanced Medicinal Chemistry II Principles of Drug Design Tentative Course Outline Instructors: Longqin Hu and John Kerrigan Direct questions and enquiries to the Course Coordinator: Longqin Hu I. Introduction
More informationCurrent Literature. Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
Current Literature Development of ighly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 ACS Med. Chem. Lett. 2018, ASAP Rational Drug Development simplification Cortistatin A 16-30 steps;
More informationBioengineering & Bioinformatics Summer Institute, Dept. Computational Biology, University of Pittsburgh, PGH, PA
Pharmacophore Model Development for the Identification of Novel Acetylcholinesterase Inhibitors Edwin Kamau Dept Chem & Biochem Kennesa State Uni ersit Kennesa GA 30144 Dept. Chem. & Biochem. Kennesaw
More informationData Quality Issues That Can Impact Drug Discovery
Data Quality Issues That Can Impact Drug Discovery Sean Ekins 1, Joe Olechno 2 Antony J. Williams 3 1 Collaborations in Chemistry, Fuquay Varina, NC. 2 Labcyte Inc, Sunnyvale, CA. 3 Royal Society of Chemistry,
More informationPerforming a Pharmacophore Search using CSD-CrossMiner
Table of Contents Introduction... 2 CSD-CrossMiner Terminology... 2 Overview of CSD-CrossMiner... 3 Searching with a Pharmacophore... 4 Performing a Pharmacophore Search using CSD-CrossMiner Version 2.0
More informationThe Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company. Sally Rose BioFocus plc
The Changing Requirements for Informatics Systems During the Growth of a Collaborative Drug Discovery Service Company Sally Rose BioFocus plc Overview History of BioFocus and acquisition of CDD Biological
More informationUser Guide for LeDock
User Guide for LeDock Hongtao Zhao, PhD Email: htzhao@lephar.com Website: www.lephar.com Copyright 2017 Hongtao Zhao. All rights reserved. Introduction LeDock is flexible small-molecule docking software,
More informationm leads Structure-based Drug Discovery - Small molecule compound databases Drug Discovery & Development (DD&D) Structure-based drug discovery
tructure-based rug iscovery tructure-based drug discovery h.. homas M. rimurer n ilico screening and drug discovery - mall molecule compound databases - Molecular descriptors - ompound filtering harmacophore
More informationSupporting Information
In Silico Identification of a ovel Hinge-Binding Scaffold for Kinase Inhibitor Discovery Yanli Wang a#, Yuze Sun b,a#, Ran Cao a#, Dan Liu a, Yuting Xie a, Li Li a, Xiangbing Qi a*, and iu Huang a* a.
More informationCreating a Pharmacophore Query from a Reference Molecule & Scaffold Hopping in CSD-CrossMiner
Table of Contents Creating a Pharmacophore Query from a Reference Molecule & Scaffold Hopping in CSD-CrossMiner Introduction... 2 CSD-CrossMiner Terminology... 2 Overview of CSD-CrossMiner... 3 Features
More informationSAMPL6 pka Challenge
SAMPL6 pka Challenge Mehtap Isik Chodera Lab, MSKCC D3R 2018 Workshop February 22nd, 2018 0 Why did we decide to organize a blind pka prediction challenge? SAMPL5 logd challenge indicated the impact of
More informationPrinciples of Drug Design
(16:663:502) Instructors: Longqin Hu and John Kerrigan Direct questions and enquiries to the Course Coordinator: Longqin Hu For more current information, please check WebCT at https://webct.rutgers.edu
More informationSynthesis of aminated xanthones: exploiting chemical routes to reach for bioactive compounds
Synthesis of aminated xanthones: exploiting chemical routes to reach for bioactive compounds Emília Sousa 1,2, *, Agostinho Lemos 1,, Ana Gomes 1,3, Sara Cravo 1, Madalena Pinto 1,2 1 Department of Chemical
More informationProgress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery
21 th /June/2018@CUGM Progress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery Kaz Ikeda, Ph.D. Keio University Self Introduction Keio University, Tokyo, Japan (Established
More informationProtein structure based approaches to inhibit Plasmodium DHODH for malaria
Protein structure based approaches to inhibit Plasmodium DHDH for malaria Peter Johnson University of Leeds, School of Chemistry email p.johnson@leeds.ac.uk Tools for protein structure based approaches
More informationThe reuse of structural data for fragment binding site prediction
The reuse of structural data for fragment binding site prediction Richard Hall 1 Motivation many examples of fragments binding in a phenyl shaped pocket or a kinase slot good shape complementarity between
More informationCOMBINATORIAL CHEMISTRY: CURRENT APPROACH
COMBINATORIAL CHEMISTRY: CURRENT APPROACH Dwivedi A. 1, Sitoke A. 2, Joshi V. 3, Akhtar A.K. 4* and Chaturvedi M. 1, NRI Institute of Pharmaceutical Sciences, Bhopal, M.P.-India 2, SRM College of Pharmacy,
More informationNMR Solutions for drug discovery
NMR Solutions for drug discovery Dr. Matteo Pennestri London, UK Bruker Users Meeting Innovation with Integrity The principle of Fragment Based Screening from efficient fragments to Drug candidates Fragment
More informationStructure-based maximal affinity model predicts small-molecule druggability
Structure-based maximal affinity model predicts small-molecule druggability Alan Cheng alan.cheng@amgen.com IMA Workshop (Jan 17, 2008) Druggability prediction Introduction Affinity model Some results
More informationUsing Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites. J. Andrew Surface
Using Bayesian Statistics to Predict Water Affinity and Behavior in Protein Binding Sites Introduction J. Andrew Surface Hampden-Sydney College / Virginia Commonwealth University In the past several decades
More informationFrom fragment to clinical candidate a historical perspective
REVIEWS Drug Discovery Today Volume 14, Numbers 13/14 July 2009 From fragment to clinical candidate a historical perspective Gianni Chessari and Andrew J. Woodhead Astex Therapeutics Ltd., 436 Cambridge
More informationNavigation in Chemical Space Towards Biological Activity. Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland
Navigation in Chemical Space Towards Biological Activity Peter Ertl Novartis Institutes for BioMedical Research Basel, Switzerland Data Explosion in Chemistry CAS 65 million molecules CCDC 600 000 structures
More informationASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS
Page109 IJPBS Volume 5 Issue 1 JAN-MAR 2015 109-114 Research Article Pharmaceutical Sciences ASSESSING THE DRUG ABILITY OF CHALCONES USING IN- SILICO TOOLS Department of Pharmaceutical Chemistry, Institute
More informationThe PhilOEsophy. There are only two fundamental molecular descriptors
The PhilOEsophy There are only two fundamental molecular descriptors Where can we use shape? Virtual screening More effective than 2D Lead-hopping Shape analogues are not graph analogues Molecular alignment
More informationDocking. GBCB 5874: Problem Solving in GBCB
Docking Benzamidine Docking to Trypsin Relationship to Drug Design Ligand-based design QSAR Pharmacophore modeling Can be done without 3-D structure of protein Receptor/Structure-based design Molecular
More informationBiologically Relevant Molecular Comparisons. Mark Mackey
Biologically Relevant Molecular Comparisons Mark Mackey Agenda > Cresset Technology > Cresset Products > FieldStere > FieldScreen > FieldAlign > FieldTemplater > Cresset and Knime About Cresset > Specialist
More informationEarly Stages of Drug Discovery in the Pharmaceutical Industry
Early Stages of Drug Discovery in the Pharmaceutical Industry Daniel Seeliger / Jan Kriegl, Discovery Research, Boehringer Ingelheim September 29, 2016 Historical Drug Discovery From Accidential Discovery
More informationIn silico pharmacology for drug discovery
In silico pharmacology for drug discovery In silico drug design In silico methods can contribute to drug targets identification through application of bionformatics tools. Currently, the application of
More information17. Biomolecular Interaction
17. Biomolecular Interaction Methods for characterizing biomolecular interactions Sequence-specific DNA binding ligands Molecular mechanisms of drug action and drug resistance In silico compound design
More informationDesign of Enzyme Literature Seminar Yun-wei Xue
Design of Enzyme 20180714 Literature Seminar Yun-wei Xue 1 Contents 1. Introduction 2. De novo design 3. Incorporation of unnatural amino acid (main paper) 2 1.1 Advantages and limitations of natural enzyme
More information1 The Binding Thermodynamics of Drug Candidates
3 1 The Binding Thermodynamics of Drug Candidates Ernesto Freire 1.1 Affinity ptimization The affinity optimization of drug candidates is a major goal in drug development. Most often, the starting points
More informationChemBioNet: Chemical Biology supported by Networks of Chemists and Biologists. Affinity Proteomics Meeting Alpbach. Michael Lisurek 15.3.
ChemBioet: Chemical Biology supported by etworks of Chemists and Biologists Affinity Proteomics Meeting Alpbach Michael Lisurek 15.3.2007 - Introduction - Equipment Screening Unit - Screening Compound
More informationSix Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study
Six Biophysical Screening Methods Miss a Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study Johannes Schiebel 1, Nedyalka Radeva 1, Stefan G. Krimmer 1, Xiaojie Wang 1, Martin
More informationLigand-receptor interactions
University of Silesia, Katowice, Poland 11 22 March 2013 Ligand-receptor interactions Dr. Pavel Polishchuk A.V. Bogatsky Physico-Chemical Institute of National Academy of Sciences of Ukraine Odessa, Ukraine
More informationIdentifying Interaction Hot Spots with SuperStar
Identifying Interaction Hot Spots with SuperStar Version 1.0 November 2017 Table of Contents Identifying Interaction Hot Spots with SuperStar... 2 Case Study... 3 Introduction... 3 Generate SuperStar Maps
More informationPlan. Day 2: Exercise on MHC molecules.
Plan Day 1: What is Chemoinformatics and Drug Design? Methods and Algorithms used in Chemoinformatics including SVM. Cross validation and sequence encoding Example and exercise with herg potassium channel:
More informationMSc Drug Design. Module Structure: (15 credits each) Lectures and Tutorials Assessment: 50% coursework, 50% unseen examination.
Module Structure: (15 credits each) Lectures and Assessment: 50% coursework, 50% unseen examination. Module Title Module 1: Bioinformatics and structural biology as applied to drug design MEDC0075 In the
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Design of screening projects General remarks Introduction Screening is done to identify new chemical substances against molecular mechanisms of a disease It is a question of
More informationNMR methods in fragment screening: theory and a comparison with other biophysical techniques
NMR methods in fragment screening: theory and a comparison with other biophysical techniques Claudio Dalvit 1,2 1 Novartis Institute for Biomedical Research, CH 4002 Basel, Switzerland 2 Department of
More informationCrystal lattice Real Space. Reflections Reciprocal Space. I. Solving Phases II. Model Building for CHEM 645. Purified Protein. Build model.
I. Solving Phases II. Model Building for CHEM 645 Purified Protein Solve Phase Build model and refine Crystal lattice Real Space Reflections Reciprocal Space ρ (x, y, z) pronounced rho F hkl 2 I F (h,
More informationHit Finding and Optimization Using BLAZE & FORGE
Hit Finding and Optimization Using BLAZE & FORGE Kevin Cusack,* Maria Argiriadi, Eric Breinlinger, Jeremy Edmunds, Michael Hoemann, Michael Friedman, Sami Osman, Raymond Huntley, Thomas Vargo AbbVie, Immunology
More informationThe Long and Rocky Road from a PDB File to a Protein Ligand Docking Score. Protein Structures: The Starting Point for New Drugs 2
The Long and Rocky Road from a PDB File to a Protein Ligand Docking Score Protein Structures: The Starting Point for New Drugs 2 Matthias Rarey Stefan Bietz Nadine Schneider Sascha Urbaczek University
More informationLecture for Molekylär bioinformatik X3 Feb Computational Chemistry in Drug Discovery. Mats Kihlén. Head of Research Informatics.
Lecture for Molekylär bioinformatik X3 Feb 24 2004 Computational Chemistry in Drug Discovery Mats Kihlén Head of Research Informatics Biovitrum AB verview» The role of computational chemistry» Basic concepts
More informationComparison of log P/D with bio-mimetic properties
Comparison of log P/D with bio-mimetic properties Klara Valko Bio-Mimetic Chromatography Consultancy for Successful Drug Discovery Solvation process First we need to create a cavity Solute molecule Requires
More informationWhat is a property-based similarity?
What is a property-based similarity? Igor V. Tetko (1) GSF - ational Centre for Environment and Health, Institute for Bioinformatics, Ingolstaedter Landstrasse 1, euherberg, 85764, Germany, (2) Institute
More informationDivCalc: A Utility for Diversity Analysis and Compound Sampling
Molecules 2002, 7, 657-661 molecules ISSN 1420-3049 http://www.mdpi.org DivCalc: A Utility for Diversity Analysis and Compound Sampling Rajeev Gangal* SciNova Informatics, 161 Madhumanjiri Apartments,
More informationHigh Throughput In-Silico Screening Against Flexible Protein Receptors
John von Neumann Institute for Computing High Throughput In-Silico Screening Against Flexible Protein Receptors H. Sánchez, B. Fischer, H. Merlitz, W. Wenzel published in From Computational Biophysics
More informationSupplementary Material
upplementary Material Molecular docking and ligand specificity in fragmentbased inhibitor discovery Chen & hoichet 26 27 (a) 2 1 2 3 4 5 6 7 8 9 10 11 12 15 16 13 14 17 18 19 (b) (c) igure 1 Inhibitors
More information